Cohort Description of Younger With AV-block
1 other identifier
observational
1,255
1 country
1
Brief Summary
Background: Disturbances of the heart's atrioventricular conduction - AV-block - may show by shortness of breath, fainting or sudden death. If AV-block is diagnosed in time pacemaker therapy may be lifesaving. AV-block in younger can be seen along with structural or ischemic heart disease, congenital heart disease (incl. congenital AV-block) storage disorders, specific muscle diseases, sarcoidosis, Borrelia infection or drug intoxication. AV-block in younger can also be seen in conditions, primarily localized to the AV-node without other cardiac disease at diagnosis. This form of AV-block is often hereditary and can be seen in families where relatives have another types of heart disease in form of fore example, cardiomyopathy, ion channel disease or sudden death. The different forms of presentation are due to the same gene mutation being expressed differently within the same family. Thus, early onset of AV-block (\<50 years) may indicate hereditary AV-conduction disorder but it can also be the first manifestation of severe ion channel disease or cardiomyopathy. Denmark has annually over 50 individuals \<50 years treated with pacemaker due to advanced AV-block. There have been no overall figures regarding the causes of advanced AV-block, and therefore no systematic approach to diagnosing this group of patients. Furthermore, the prevalence of individuals with a genetic cause of AV-block is unknown and presumably an often overlooked diagnosis among younger patients with advanced AV-blok. There are no data on disease progression after diagnosis, and therefore there is no evidence-based knowledge about how these patients should be followed after diagnosis. With modern gene technology, a range of new, yet unknown genes with potentially pathogenic mutations is likely to be identified. Identification of such genes, and the development of a strategy for systematic approach to diagnose younger patients with AV-block, will enable presymptomatic genetic screening of relatives and implementation of evidence-based, preventive treatment with pacemaker and/or medical treatment for heart failure based on a specific genetic predisposition for development of AV-block with or without heart failure. Hypotheses: In a significant proportion of younger patients with advanced AV-block the underlying cause is unknown. Objective: To investigate the prevalence and causes of advanced AV-block in younger patients in Denmark and describe the current diagnostics. Method: The study is a cross sectional study. The patients for this study are identified from Danish Pacemaker and ICD Register. The investigators will review medical records and obtain clinical information and test results (see detailed description). Perspectives: This study is the first part of a large study of AV-block in younger patients in Denmark. The overall goal, is to increase knowledge about the causes of and disease progression after the diagnosis of advanced AV-block in young patients which could lead to a significant improvement in the treatment of this patient group and may lead to a customized choice of pacemaker type in the future and perhaps additional medical treatment in this patient group. This could potentially lead to a reduction in both their morbidity mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 4, 2017
CompletedFirst Posted
Study publicly available on registry
January 18, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2018
CompletedJanuary 18, 2017
January 1, 2017
1.6 years
January 4, 2017
January 13, 2017
Conditions
Outcome Measures
Primary Outcomes (12)
Prevalence of structural heart disease as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of ischemic heart disease as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of congenital heart disease as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of congenital AV-block
01.01.1996 - 31.12.2015
Prevalence of muscular dystrophy as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of sarcoidosis as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of lyme disease as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of genetic cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of complications to operation as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of complications to radio frequency ablation as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of endocarditis as cause of AV-block
01.01.1996 - 31.12.2015
Prevalence of unknown cause of AV-block
01.01.1996 - 31.12.2015
Interventions
Eligibility Criteria
All patients in Denmark with AV-block who were treated with pacemaker for the first time between 01.01.1996 - 31.12.2015 with age at implantation \<50 years will be included in the study (n=1,255 patients).
You may qualify if:
- All patients in Denmark
- Treated with pacemaker due to AV-block
- Implanted for the first time between 01.01.1996 - 31.12.2015
- Age at implantation \<50 years
You may not qualify if:
- Non
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of cardiology, Research, Aarhus University Hospital, Denmark
Aarhus, 8200, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 4, 2017
First Posted
January 18, 2017
Study Start
January 1, 2017
Primary Completion
August 1, 2018
Last Updated
January 18, 2017
Record last verified: 2017-01